IRB #

STUDY00017027

Title

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of different combinations of cancer drugs compared to either nivolumab and ipilimumab or one another in participants with metastatic kidney cancer.

Medical Condition(s)

Kidney Cancer

Eligibility Criteria

Eligibility
*Must be 18 years of age or older.
*Subject have confirmed diagnosis of kidney cancer.
*Patients cannot have had any other treatment for their kidney cancer
*Have tumor samples available for testing
*Subject's medical history will be reviewed in detail for study eligibility.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Patients will stay in the study as long as they receive clinical benefit.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Bristol-Myers Squibb

Recruitment End

07/15/2020

Compensation Provided

No


Go Back